Emerging evidence supports the use of SGLT2 inhibitors in improving hepatic steatosis, reducing liver fibrosis, and enhancing metabolic parameters in patients with NAFLD and type 2 diabetes [6]. This evidence concerns the gene SLC5A2 and Hepatic steatosis.